Eli Lilly and Company $LLY Stock Position Raised by Sonora Investment Management Group LLC

Sonora Investment Management Group LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 3,220 shares of the company’s stock after acquiring an additional 170 shares during the quarter. Sonora Investment Management Group LLC’s holdings in Eli Lilly and Company were worth $2,510,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Brighton Jones LLC boosted its position in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the period. AdvisorNet Financial Inc boosted its position in shares of Eli Lilly and Company by 3.4% in the first quarter. AdvisorNet Financial Inc now owns 2,436 shares of the company’s stock worth $2,012,000 after buying an additional 79 shares during the period. Spartan Planning & Wealth Management boosted its position in shares of Eli Lilly and Company by 91.8% in the first quarter. Spartan Planning & Wealth Management now owns 1,427 shares of the company’s stock worth $1,179,000 after buying an additional 683 shares during the period. Finally, Rothschild Investment LLC boosted its position in Eli Lilly and Company by 5.4% during the first quarter. Rothschild Investment LLC now owns 10,392 shares of the company’s stock valued at $8,583,000 after purchasing an additional 533 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks acquired 1,632 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last ninety days. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Up 1.4%

LLY opened at $724.73 on Friday. The business has a 50 day moving average price of $734.15 and a 200 day moving average price of $766.82. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market cap of $685.93 billion, a P/E ratio of 47.37, a price-to-earnings-growth ratio of 1.01 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the firm earned $3.92 EPS. The firm’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Ratings Changes

LLY has been the subject of a number of research reports. Leerink Partners reissued a “market perform” rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. JPMorgan Chase & Co. reduced their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. Berenberg Bank restated a “hold” rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Finally, Guggenheim dropped their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $939.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.